Human pharmacological studies of a defined low molecular weight heparin fraction (Fragmin) evidence for a simultaneous inhibition of factor Xa and IIa (thrombin).
The effect of a low molecular weight heparin (Fragmin) (20-80 U/kg) was studied in 10 healthy male volunteers after intravenous administration. Clotting abnormalities are extensive shortly after injection, lasting for 1-2 hours depending on heparin dosage. Dilute thrombin time, showing a close correlation to anti-F-Xa activity, is as sensitive as anti-F-Xa. The parallel time course of dilute thrombin time and anti-F-Xa activity clearly demonstrates that LMWH has an effect on F-IIa lasting as long as that of F-Xa. After subcutaneous administration clotting abnormalities are only slight with 40-60 U/kg, in contrast to the intravenous study. The platelet system remains unchanged.
Andrassy
K
K
Department of Nephrology, University Medical Hospital, Heidelberg, FRG.
Mörike
K
K
Koderisch
J
J
Weber
E
E
D000328:Adult; D000925:Anticoagulants / Q000494:pharmacology; D001760:Bleeding Time; D015951:Factor Xa; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008297:Male; D008970:Molecular Weight; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D011516:Prothrombin / Q000037:antagonists & inhibitors*; D011517:Prothrombin Time; D012697:Serine Endopeptidases; D015842:Serine Proteinase Inhibitors / Q000494:pharmacology*
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D010975:Platelet Aggregation Inhibitors; D015842:Serine Proteinase Inhibitors; D011516:Prothrombin; C025337:Factor IIa; D012697:Serine Endopeptidases; D015951:Factor Xa